CURX
HEALTHCARECuranex Pharmaceuticals Inc Common Stock
AI Insight
What's Moving CURX Today?
No stock-specific AI insight has been generated for CURX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.26$9.18
$0.27
Fundamentals
Market Cap$8M
P/E Ratio—
EPS$-0.02
Dividend Yield—
Dividend / Share—
ROE-85.3%
Profit Margin—
Debt / Equity—
Trading
Volume53K
Avg Volume (10D)—
Shares Outstanding28.3M
CURX News
14 articles- Curanex Reports First Quarter 2026 Business Progress as Phyto-N Advances Toward Planned FDA SubmissionYahoo Finance·May 14, 2026
- Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic DeclineYahoo Finance·Apr 8, 2026
- Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive CareYahoo Finance·Apr 6, 2026
- Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company’s Evolution Into a Broader Therapeutics Development CompanyYahoo Finance·Apr 2, 2026
- Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND SubmissionGlobeNewswire Inc.·Mar 30, 2026
- Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND SubmissionYahoo Finance·Mar 18, 2026
- Curanex Expands Scientific Advisory Board With Two Distinguished ResearchersYahoo Finance·Mar 12, 2026
- Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory BoardYahoo Finance·Mar 11, 2026
- Curanex Forms World Class Scientific Advisory BoardYahoo Finance·Mar 5, 2026
- Curanex Provides Operational Update on Key Regulatory MilestonesYahoo Finance·Feb 25, 2026
- Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and EngagementYahoo Finance·Oct 22, 2025
- Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by UnderwritersYahoo Finance·Sep 12, 2025
- Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public OfferingYahoo Finance·Aug 27, 2025
- Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public OfferingYahoo Finance·Aug 26, 2025
All 14 articles loaded
Price Data
Open$0.28
Previous Close$0.28
Day High$0.29
Day Low$0.27
52 Week High$9.18
52 Week Low$0.26
52-Week Range
$0.26$9.18
$0.27
Fundamentals
Market Cap$8M
P/E Ratio—
EPS$-0.02
Dividend Yield—
Dividend / Share—
ROE-85.3%
Profit Margin—
Debt / Equity—
Trading
Volume53K
Avg Volume (10D)—
Shares Outstanding28.3M
About Curanex Pharmaceuticals Inc Common Stock
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. The company is headquartered in Jericho, New York.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—